Related Experiment Video
Updated: Aug 24, 2026

Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks
Published on: November 10, 2016
Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator
Helena Erlandsson Harris1, Ulf Andersson
1Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden. Helena.Erlandsson.Harris@cmm.ki.se
Abstract:
The intranuclear architectural protein that is termed high mobility group box chromosomal protein 1 (HMGB1) was recently identified as a potent proinflammatory mediator when present extracellularly. HMGB1 has been demonstrated to be a long-searched-for nuclear danger signal passively released by necrotic, as opposed to apoptotic, cells that will induce inflammation. Furthermore, HMGB1 can also be actively secreted by stimulated macrophages or monocytes in a process requiring acetylation of the molecule, which enables translocation from the nucleus to secretory lysosomes. Subsequent transport out of the cells depends on a secretion signal mediated by either extracellular lysophophatidyl-choline or ATP. HMGB1 passively released from necrotic cells and HMGB1 actively secreted by inflammatory cells are thus molecularly different. Extracellular HMGB1 acts as a cytokine by signaling via the receptor for advanced glycated end-products and via members of the Toll-like receptor family. The initiated inflammatory responses include the production of multiple cytokines, chemoattraction of certain stem cells, induction of vascular adhesion molecules and impaired function of intestinal epithelial cells. Therapeutic administration of HMGB1 antagonists rescues mice from lethal sepsis, even when initial treatment is delayed for 24 h after the onset of infection, establishing a clinically relevant therapeutic window that is significantly wider than for other known cytokines.
Insights
High mobility group box chromosomal protein 1 (HMGB1) acts as an extracellular inflammatory mediator. HMGB1 antagonists show therapeutic potential against lethal sepsis, even with delayed treatment.
Area of Science:
- Immunology
- Cell Biology
- Molecular Biology
Background:
- High mobility group box chromosomal protein 1 (HMGB1) is an intranuclear architectural protein.
- Extracellular HMGB1 functions as a potent proinflammatory mediator and a nuclear danger signal.
- HMGB1 can be passively released by necrotic cells or actively secreted by immune cells.
Purpose of the Study:
- To elucidate the dual role of HMGB1 in inflammation.
- To investigate the mechanisms of HMGB1 release and its signaling pathways.
- To evaluate the therapeutic potential of HMGB1 antagonists in sepsis.
Main Methods:
- Analysis of HMGB1 release mechanisms (passive vs. active secretion).
- Investigation of HMGB1 signaling via receptor for advanced glycated end-products and Toll-like receptors.
- Assessment of HMGB1 antagonist efficacy in a lethal sepsis mouse model.
Main Results:
- Passively released and actively secreted HMGB1 exhibit molecular differences.
- Extracellular HMGB1 triggers inflammatory responses, including cytokine production and stem cell chemoattraction.
- Therapeutic administration of HMGB1 antagonists demonstrated significant efficacy in rescuing mice from lethal sepsis, even with delayed treatment.
Conclusions:
- HMGB1 is a critical mediator of inflammation with distinct release mechanisms.
- Targeting HMGB1 offers a promising therapeutic strategy for sepsis with a wide therapeutic window.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Acute Inflammation III: Local and Systemic Effects
Nuclear Export
NES are of three types- the canonical 10-residue long leucine-rich signal and other...
Acute Inflammation I: Inflammatory Response